Letter to the Editor

Reversible Acute Hepatitis Induced by Rosuvastatin

Authors: Alessandro Oteri, PharmD, Maria Antonietta Catania, MD, Alessandra Russo, MD, Francesco Salvo, MD, Luciano Giacci, MD, Achille Patrizio Caputi, MD, Giovanni Polimeni, PharmD

Abstract

To the Editor:


Hepatic adverse reactions are a class-effect of statins, rarely leading to serious liver damage. The current report describes reversible acute hepatitis in a patient treated with rosuvastatin.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743–759.
 
2.Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005;41:690–695.
 
3.Seehusen DA, Asplund CA, Johnson DR, et al. Primary evaluation and management of statin therapy complications. South Med J 2006;99:250–256.
 
4.Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig Liver Dis 2006;38:772–777.
 
5.Nezasa K, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002;30:1158–1163.